Joyce Ronan, Herlihy Emer, Lavan Naomi, Gillham Charles
Department of Radiation Oncology, Galway University Hospital, Galway, Ireland.
St Lukes Radiation Oncology Network, Dublin, Ireland.
Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):13-27. doi: 10.1016/j.ijrobp.2024.07.2151. Epub 2024 Aug 5.
Hypofractionated radiation therapy is being used more frequently for many common cancer sites. Conventionally fractionated radiation therapy treatment regimens have remained the standard of care when radiation therapy is indicated for soft tissue sarcoma (STS). The aim of this study was to systematically review published data on the use of preoperative hypofractionated radiation therapy as part of a curative treatment paradigm in patients with STS. Herein, we summarize current evidence for the use of hypofractionated radiation therapy in the preoperative treatment of STS.
We conducted a database search for prospectively or retrospectively collected data on patients with a diagnosis of STS treated with hypofractionated radiation therapy. Studies evaluating STS of all histologic subtypes affecting extremities or trunks were included in the search. Articles were screened by 2 independent reviewers for inclusion in this review. Patient, treatment, toxicity, and outcome data were recorded and collated from selected studies.
Twenty-five articles are included in this review. Nine prospective trials have been published since 2020. Dose fractionations range from 25 to 40 Gy in 5 fractions or 28-42.75 Gy in 8-15 fractions. Local control and overall survival outcomes are consistent with historical data for conventionally fractionated radiation therapy. Acute toxicity and wound complication rates are in keeping with acceptable results. Late toxicity data are limited and require longer follow-up. Rates of pathologic complete response are promising across all studies.
There is a growing body of evidence supporting hypofractionation as safe and effective in the preoperative treatment of STS. This review highlights potential areas that could be further investigated to optimize preoperative treatment for STS.
超分割放射治疗在许多常见癌症部位的应用越来越频繁。当软组织肉瘤(STS)需要进行放射治疗时,传统分割放射治疗方案仍是标准的治疗方法。本研究的目的是系统回顾已发表的关于术前超分割放射治疗作为STS患者根治性治疗模式一部分的数据。在此,我们总结了超分割放射治疗在STS术前治疗中的现有证据。
我们对前瞻性或回顾性收集的接受超分割放射治疗的STS患者数据进行了数据库检索。检索纳入了评估所有影响四肢或躯干的组织学亚型的STS的研究。由2名独立 reviewers 筛选文章以纳入本综述。从选定的研究中记录并整理患者、治疗、毒性和结局数据。
本综述纳入了25篇文章。自2020年以来已发表了9项前瞻性试验。剂量分割范围为5次分割25至40 Gy或8至15次分割28 - 42.75 Gy。局部控制和总生存结局与传统分割放射治疗的历史数据一致。急性毒性和伤口并发症发生率与可接受的结果相符。晚期毒性数据有限,需要更长时间的随访。所有研究中的病理完全缓解率都很有前景。
越来越多的证据支持超分割在STS术前治疗中是安全有效的。本综述强调了可能需要进一步研究以优化STS术前治疗的潜在领域。